- cafead Oct 21, 2021 at 10:52: AM
via
article source
- Alopecia areata patients receiving Olumiant were much more likely to experience significant scalp hair regrowth than those who took a placebo.
- Olumiant probably won't quite be a blockbuster for Eli Lilly, but it will be a meaningful growth driver for the stock regardless.
- Eli Lilly is a dividend growth stock that investors should consider.
article source